RUA Life Sciences PLC Update re Notice of Annual General Meeting (6468I)
13 Agosto 2021 - 8:43AM
UK Regulatory
TIDMRUA
RNS Number : 6468I
RUA Life Sciences PLC
13 August 2021
13 August 2021
RUA Life Sciences plc
("RUA" or the "Company")
2021 Notice of Annual General Meeting - Correction
RUA Life Sciences (AIM:RUA) , the holding company of a group of
medical device businesses focused on the exploitation of the
world's leading long-term implantable biostable polymer
(Elast-Eon(TM) ), announces that resolution numbered 7 ("Resolution
7") set out in its Notice of 2021 Annual General Meeting (the
"Notice") to be held on Tuesday 31 August 2021 ("AGM") contained
certain typographical errors. Resolution 7 refers to proposed
authorities to allot (or grant rights over) new ordinary shares in
the capital of RUA pursuant to either an open offer or a rights
issue. As set out in the explanatory notes to the Notice, the
intention is that such authorities comply with the Investment
Association's guidelines and be limited to an aggregate nominal
value equal to (i) approximately 33% with regard to paragraph 7.1
of Resolution 7, and (ii) approximately 66% in relation to
paragraph 7.2 of Resolution 7.
Accordingly, the maximum number of new ordinary shares which may
be allotted pursuant to (a) paragraph 7.1 should be equal to an
aggregate nominal value of GBP369,746 (not GBP396,746 as currently
stated), and (b) paragraph 7.2 should be equal to an aggregate
nominal value of GBP739,492 (not GBP793,492 as currently stated). A
procedural resolution to approve such corrected Resolution 7 will
be proposed at the AGM. A copy of the corrected Notice is available
to view in the "Investor Relations" section of RUA's website at
https://rualifesciences.com/investor-relations/ . The corrected
Notice is also available for inspection at RUA's registered office
(c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2
4SQ, UK). As these were clerical errors, no new Notice is required
to be sent out to shareholders.
If shareholders have any questions in connection with the
proposed business of the AGM, or the contents of this
communication, they should email RUA's Company Secretary , Kate
Full, at Kate.Full@rualifesciences.com.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
Shore Capital (Nominated Adviser and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0)20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
enabling medical devices with Elast-Eon (TM) , the world's leading
long-term implantable polyurethane.
Whether it is licensing Elast-Eon (TM) , manufacturing a device
or component, or developing next generation medical devices, a RUA
Life Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and 14 years of successful clinical use, RUA's
polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Medical End-to-end contract developer and manufacturer
: of medical devices and implantable fabric
specialist.
RUA Biomaterials Licensor of Elast-Eon (TM) polymers to the
: medical device industry.
RUA Vascular: Development of large bore polymer sealed grafts
and soft tissue patches.
RUA Structural Development of tri leaflet polymeric heart
Heart : valves.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUOOORAKUWAAR
(END) Dow Jones Newswires
August 13, 2021 09:43 ET (13:43 GMT)
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De May 2023 a May 2024